Method
What receptors does CBG bind?
CBG has a published in-vitro receptor profile: CB1 antagonism, which is the chemistry behind calling it non-intoxicating; 5-HT1A antagonism, with an Atlas-reported KB of about 51.9 nM; and TRP-channel activity as a TRPV1/TRPV2 agonist–desensitiser and TRPM8 antagonist. α2-adrenoceptor agonism is reported as highly potent in vitro, and a human blood-pressure effect is hypothesised from that but has not been measured. Activity validated in vitro is not an outcome in a person.
| Target | In-vitro report | Human outcome |
|---|---|---|
| CB1 | Antagonist | Not an intoxication claim |
| 5-HT1A | Antagonist, KB ≈ 51.9 nM | Not a mood claim |
| TRPV1 / TRPV2 | Agonist–desensitiser | Not a pain claim |
| TRPM8 | Antagonist | Not a cooling claim |
| α2-adrenoceptor | Agonist, potent in vitro | BP in people: hypothesized |
Origin
The numbers and targets come from CBG Atlas’s monograph grades. Peregrine does not run binding assays and does not use these figures in marketing.
Established
- In-vitro CB1 antagonism.
- In-vitro 5-HT1A antagonism (Atlas: KB ≈ 51.9 nM).
- In-vitro TRPV1/TRPV2 agonist–desensitiser; TRPM8 antagonist.
Not yet
- α2 blood-pressure pharmacology in humans.
- Any structure/function claim built from a binding constant.
Questions
Does CB1 antagonism mean CBG blocks THC?
No. CB1 antagonism describes how CBG behaves at the receptor in a laboratory assay. It says nothing about what happens when the two are taken together in a person.
Evidence language follows CBG Atlas (Peregrine-funded; editorial independence). Not medical advice. Not a disease claim.
Related
Educational, not medical advice. Nothing here diagnoses, treats, cures or prevents any disease. Wholesale isolates are ingredients, not finished supplements. Education is aligned with CBG Atlas, which Peregrine funds without editorial control.